Ann: Argenica to Progress Clinical Development in TBI, page-4

Thanks Alphabette, will watch shortly.

Was going back through some old announcements last night to try find those options one of our directors took up. Dianne Angus who has been with us 18 months accepted options about 12 months ago with a strike price of 93 cents. Doing some digging this morning the last role she took up before joining Argenica was joining the Neuron Pharmaceuticals board in July of 2018. Two years later the stock began its momentous run where it went on to 10-fold in price (20-fold from the lows).